Castle Biosciences (CSTL) Expands On New Clinical Data, Is It Still 19% Below Fair Value?
Simply Wall Street
Castle Biosciences (CSTL) has seen a significant stock surge of 47.37% in 90 days following new clinical data for its AdvanceAD-Tx atopic dermatitis test, a new Scottsdale lab, and upcoming DecisionDx-Melanoma data. Despite this rise, the company is considered by some analysts to be 19% undervalued with a fair value of $44.00, driven by its expanding test menu and role in precision medicine. However, potential risks include unfavorable payer decisions and rising commercial costs.
Read the full story
This is a short summary. The complete article is published by Simply Wall Street.
Headline and summary aggregated from public news feeds. For information only — not financial advice.